Exercise preconditioning protects against doxorubicin-induced cardiac dysfunction

Medicine and Science in Sports and Exercise

Volumn 40, Issue 5, 2008, Pages 808-817

  Hydock, David S ^a   Lien, Chia Ying ^a   Schneider, Carole M ^a   Hayward, Reid ^a  

^a UNIVERSITY OF NORTHERN COLORADO   (United States)

Author keywords

Anthracycline; Cardiomyopathy; Echocardiography; Physical activity

Indexed keywords

DOXORUBICIN; MYOSIN HEAVY CHAIN; SODIUM CHLORIDE; ANTINEOPLASTIC ANTIBIOTIC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; ENDURANCE; EX VIVO STUDY; EXERCISE; HEART DISEASE; HEART PROTECTION; HEART VENTRICLE FUNCTION; IN VIVO STUDY; MALE; NONHUMAN; RAT; SITTING; SPRAGUE DAWLEY RAT; TRANSTHORACIC ECHOCARDIOGRAPHY; TREADMILL EXERCISE; ANALYSIS OF VARIANCE; ANIMAL; BLOOD; BLOOD PRESSURE MEASUREMENT; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOOD PRESSURE DETERMINATION; DOXORUBICIN; ECHOCARDIOGRAPHY; HEART; MALE; MYOSIN HEAVY CHAINS; PHYSICAL CONDITIONING, ANIMAL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 52149101478     PISSN: 01959131     EISSN: 15300315     Source Type: Journal    
DOI: 10.1249/MSS.0b013e318163744a     Document Type: Article

References (41)

1. Allen DL, Harrison BC, Maass A, Bell ML, Byrnes WC, Leinwand LA. Cardiac and skeletal muscle adaptations to voluntary wheel running in the mouse. J Appl Physiol. 2001; 90(5):1900-8.
2. Andreadou I, Sigala F, Iliodromitis EK, et al. Acute doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stress. J Mol Cell Cardiol. 2007;42(3):549-58.
3. Aragno M, Mastrocola R, Medana C, et al. Oxidative stress-dependent impairment of cardiac-specific transcription factors in experimental diabetes. Endocrinology. 2006;147(12):5967-74.
4. Arnolda L, McGrath B, Cocks M, Sumithran E, Johnston C. Adriamycin cardiomyopathy in the rabbit: an animal model of low output cardiac failure with activation of vasoconstrictor mechanisms. Cardiovasc Res. 1985;19(6):378-82.
5. Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res. 2000;60(7):1789-92.
6. Belham, M, Kruger A, Mepham S, Faganello G, Pritchard C. Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy. Eur J Heart Fail. 2007;9(4): 409-14.
7. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72: 248-54.
8. Chaiswing L, Cole MP, St Clair DK, Ittarat W, Szweda LI, Obcrley TD. Oxidative damage precedes nitrative damage in adriamycin-induced cardiac mitochondrial injury. Toxicol Pathol. 2004;32(5):536-47.
9. Chen C, Conklin BS, Ren Z, Zhong DS. Homocysteine decreases endothelium-dependent vasorelaxation in porcine arteries. J Surg Res. 2002;102(1):22-30.
10. Chicco AJ, Schneider CM, Hayward R. Exercise training attenuates acute doxorubicin-induced cardiac dysfunction. J Cardiovasc Pharmacol 2006;47(2):182-9.
11. Christie J, Sheldahl LM, Tristani FE, Sagar KB, Ptacin MJ, Wann S. Determination of stroke volume and cardiac output during exercise: comparison of two-dimensional and Doppler echocar-diography, Fick oximetry, and thermodilution. Circulation. 1987; 76(3):539-47.
12. de Beer EL, Bottone AE, van Der Velden J, Voest EE. Doxorubicin impairs crossbridge turnover kinetics in skinned cardiac trabeculae after acute and chronic treatment. Mol Pharmacol. 2000;57(6):1152-7.
13. Gorodetskaya EA, Dugin SF, Golikov MA, Kapelko VI, Medvedev OS. The cardiac contractile function and hemodynamic control in rats after chronic adriamycin treatment. Can J Physiol Pharmacol. 1990;68(2):211-5.
14. Hayward R, Hydock DS. Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J Am Assoc Lab Anim Sci. 2007;46(4): 20-32.
15. Hayward R, Ruangthai R, Schneider CM, Hyslop RM, Strange R, Westerlind KC. Training enhances vascular relaxation after chemotherapy-induced vasoconstriction. Med Sci Sports Exercv. 2004;36(3):428-34.
16. Herron TJ, Korte FS, McDonald KS. Loaded shortening and power output in cardiac myocytes are dependent on myosin heavy chain isoform expression. Am J Physiol Heart Circ Physiol. 2001; 281(3):H1217-22.
17. Herron TJ, McDonald KS. Small amounts of alpha-myosin heavy chain isoform expression significantly increase power output of rat cardiac myocyte fragments. Circ Res. 2002;90(11):1150-2.
18. Jin H, Yang R, Li W, et al. Effects of exercise training on cardiac function, gene expression, and apoptosis in rats. Am J Physiol Heart Circ Physiol. 2000;279(6):H2994-3002.
19. Konhilas JP, Watson PA, Maass A, et al. Exercise can prevent and reverse the severity of hypertrophic cardiomyopathy. Circ Res. 2006;98(4):540-8.
20. Korte FS, Herron TJ, Rovetto MJ, McDonald KS. Power output is linearly related to MyHC content in rat skinned myocytes and isolated working hearts. Am J Physiol Heart Circ Physiol. 2005; 289(2):H801-12.
21. Krenz M, Sanbe A, Bouyer-Dalloz F, et al. Analysis of myosin heavy chain functionality in the heart. J Biol Chem. 2003;278(19): 17466-74.
22. Lennon SL, Quindry J, Hamilton KL, et al. Loss of exercise-induced cardioprotection after cessation of exercise. J Appl Physiol. 2004;96(4):1299-305.
23. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23(12):2629-36.
24. Monnet E, Orton EC. A canine model of heart failure by intracoronary adriamycin injection: hemodynamic and energetic results. J Card Fail. 1999;5(3):255-64.
25. Morris GS, Prevost MC, Nelson AG. Morderate diabetes alters myosin isoenzyme distribution in cardiac but not skeletal muscle of male rats. Life Sci. 1996;58(10):833-8.
26. Natali AJ, Wilson LA, Peckham M, Turner DL, Harrison SM, White E. Different regional effects of voluntary exercise on the mechanical and electrical properties of rat ventricular myocytes. J Physiol. 2002; 541(Pt. 3):863-75.
27. Neilan TG, Doherty GA, Chen G, et al. Disruption of COX-2 modulates gene expression and the cardiac injury response to doxorubicin. Am J Physiol Heart Circ Physiol. 2006;291(2)-H532-6.
28. Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer. 2002;86(11): 1697-700.
29. Oliveira PJ, Wallace KB. Depletion of adenine nucleotide translocator protein in heart mitochondria from doxorubicin-treated rats - relevance for mitochondrial dysfunction. Toxicology. 2006; 220(2-3): 160-8.
30. Quindry J, French J, Hamilton K, Lee Y, Mehta JL, Powers S. Exercise training provides cardioprotection against ischemia-reperfusion induced apoptosis in young and old animals. Exp Gerontol. 2005;40(5):416-25.
31. Rabelo E, De Angelis K, Bock P, et al. Baroreflex sensitivity and oxidative stress in adriamycin-induced heart failure. Hypertension. 2001;38(3 Pt. 2):576-80.
32. Seymour L, Bramwell V, Moran LA. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer Prev Control. 1999;3(2):145-59.
33. Starnes JW, Taylor RP, Ciccolo JT. Habitual low-intensity exercise does not protect against myocardial dysfunction after ischemia in rats. Eur J Cardiovasc Prev Rehabil. 2005; 12(2): 169-74.
34. Talmadge RJ, Roy RR. Electrophoretic separation of rat skeletal muscle myosin heavy-chain isoforms. J Appl Physiol. 1993;75(5): 2337-40.
35. Tardiff JC, Hewett TE, Factor SM, Vikstrom KL, Robbins J, Leinwand LA. Expression of the beta (slow)-isoform of MHC in the adult mouse heart causes dominant-negative functional effects. Am J Physiol Heart Circ Physiol. 2000;278(2): H412-9.
36. Taylor RP, Olsen ME, Stames JW. Improved postischemic function following acute exercise is not mediated by nitric oxide synthase in the rat heart. Am J Physiol Heart Circ Physiol. 2007; 292(1):H601-7.
37. Tokarska-Schlattner M, Wallimann T, Schlattner U. Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin. C R Biol. 2006;329(9):657-68.
38. Tokarska-Schlattner M, Zaugg M, da Silva R, et al. Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply. Am J Physiol Heart Circ Physiol. 2005; 289(1):H37-47.
39. Vidal RF, Eksborg S, Sundberg M, Carlberg M, Elfsson B, Andersson BS. Doxorubicin- and daunorubicin-induced energy deprivation and nucleotide degradation in isolated cardiomyocytes. Toxicology. 1996;114(1):1-10.
40. Villani F, Meazza R, Materazzo C. Non-invasive monitoring of cardiac hemodynamic parameters in doxorubicin-treated patients: comparison with echocardiography. Anlicancer Res. 2006;26(1B): 797-801.
41. Wakasugi S, Fischman AJ, Babich JW, et al. Myocardial substrate utilization and left ventricular function in adriamycin cardiomyopathy. J Nucl Med. 1993;34(9):1529-35.